Skip to main content

Table 5 Attack frequency in patients with HAE-PLG before and during long-term prophylaxis

From: Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene

Patient No.MedicationSymptomatic years before LTPAttacks during symptomatic years before LTPYears with LTPAttacks during LTPReduction in attack frequency (%)
Progestins*
 1desogestrel4754820
 5desogestrel74322750
 15desogestrel121352260
 23desogestrel78310100
 24desogestrel1021031477.6
 25desogestrel61020100
Antifibrinolytics
 20TXA6982940100
 26TXA713140100
 27TXA151711281.8
Attenuated androgens**
 13danazol1346180100
 20danazol586980.3250
 27danazol15170.30100
  1. C1-INH C1 inhibitor, HAE hereditary angioedema, HAE-PLG HAE with normal C1-INH and the c.988A>G (p.K330E) variant in the PLG gene, LTP long-term prophylaxis, TXA tranexamic acid
  2. *after discontinuing estrogen-containing oral contraceptives
  3. **dose range 100 mg to 200 mg danazol daily